IMS Health and Foundation Medicine have entered a partnership to advance the understanding and effectiveness of precision therapies to treat cancer.

Under the collaboration, IMS Health’s Real-World Evidence (RWE) platform will combine with Foundation Medicine’s comprehensive cancer genomic profiles knowledgebase.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The offering will enable commercial, medical and outcomes research teams in biopharma and life sciences companies to gain insights to rapidly assess health outcomes and effectiveness.

"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs."

This will help improve cancer care by better connecting patients to the right targeted therapies at the right time.

IMS Health Real-World Evidence Solutions vice-president and general manager Jon Resnick said: "As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions and outcomes for patient populations living with those cancers.

"This collaboration with Foundation Medicine extends our Real-World Evidence platform, uniquely linking claims, EMR and biomarker data at the anonymous patient level to drive a complete understanding of the oncology patient journey and improve clinical development and commercialisation strategies."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The oncologic insights will be powered by IMS Health’s scalable and secure RWE platform, Evidence 360 and FoundationCORE, a molecular information knowledgebase.

Evidence 360 helps clients extract, analyse and visualise real-world data to better understand and measure healthcare outcomes.

FoundationCORE contains comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact